Novel therapeutic approaches to post-infarction remodelling

Cardiovascular Research

Volumn 94, Issue 2, 2012, Pages 293-303

  Fraccarollo, Daniela ^a   Galuppo, Paolo ^a   Bauersachs, Johann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Fibroblasts; Ischaemia; Macrophages; MicroRNAs; Myocardial infarction; Progenitor cells; Remodelling

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; MICRORNA; TRANSFORMING GROWTH FACTOR BETA;

ACUTE HEART INFARCTION; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL THERAPY; CONGESTIVE CARDIOMYOPATHY; EMBRYONIC STEM CELL; GENE THERAPY; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC CARDIOMYOPATHY; MACROPHAGE; MESENCHYMAL STEM CELL; MONOCYTE; MYOBLAST; PHENOTYPE; POSTINFARCTION CARDIOVASCULAR REMODELLING; PRIORITY JOURNAL; STEM CELL; WOUND HEALING;

GENE THERAPY; HUMANS; MICRORNAS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; STEM CELL TRANSPLANTATION; VENTRICULAR REMODELING;

EID: 84860143671     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs109     Document Type: Article

References (130)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172. (Pubitemid 20119612)
2. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:356-367. (Pubitemid 43151469)
3. Dorn GW 2nd. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 2009;6:283-291.
4. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009;81:519-527.
5. Dixon JA, Spinale FG. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol 2011;73:47-68.
6. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011;4:98-108.
7. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009;81:474-481.
8. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47. (Pubitemid 34020764)
9. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010;48:504-511.
10. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58: 88-111.
11. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;17:581-588.
12. Troidl C, Möllmann H, Nef H, Masseli F, Voss S, Szardien S et al. Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 2009;13:3485-3496.
13. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 2008;51:905-914. (Pubitemid 351654703)
14. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005;45: 657-687. (Pubitemid 40261821)
15. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010;7: 30-37.
16. Fraccarollo D, Galuppo P, Bauersachs J, Ertl G. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002;54:559-567. (Pubitemid 34595414)
17. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89: 151-163. (Pubitemid 24026485)
18. Shyu KG,Wang BW, Chen WJ, Kuan P, Hung CR. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 2010;12:219-226.
19. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-985. (Pubitemid 32803872)
20. Carluccio E, Biagioli P, Alunni G, Murrone A, Giombolini C, Ragni T et al. Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol 2006;47:969-977.
21. Van Bommel RJ, Delgado V, Schalij MJ, Bax JJ. Critical appraisal of the use of cardiac resynchronization therapy beyond current guidelines. J Am Coll Cardiol 2010;56: 754-762.
22. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 2010;122:985-992.
23. Carluccio E, Biagioli P, Alunni G, Murrone A, Pantano P, Biscottini E et al. Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony. JACC Cardiovasc Imaging 2011;4:1067-1076.
24. Sachse FB, Torres NS, Savio-Galimberti E, Aiba T, Kass DA, Tomaselli GF et al. Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ Res 2012;110:588-597.
25. Bauersachs J. Regulation of myocardial fibrosis by MicroRNAs. J Cardiovasc Pharmacol 2010;56:454-459.
26. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011;469:336-342.
27. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008;79:562-570.
28. Gladka MM, da Costa Martins PA, De Windt LJ. Small changes can make a big difference-microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol 2011;52: 72-82.
29. Zhu H, Fan G. Role of microRNA in riperfused myocardium towards post-infarct remodeling. Cardiovasc Res 2011;94:284-292.
30. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103:18255-18260. (Pubitemid 44871645)
31. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31:367-373. (Pubitemid 350127777)
32. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007; 116:258-267. (Pubitemid 47196561)
33. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009;119:1263-1271.
34. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res 2011;109:334-347.
35. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
36. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82: 21-29.
37. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009;284:29514-29525.
38. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-13032.
39. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009;324:1710-1713.
40. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011; 124:720-730.
41. Schroen B, Heymans S. Small but smart-microRNAs in the center of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and aging. Cardiovasc Res 2012;93:605-613.
42. Hu S, Huang M, Nguyen PK, Gong Y, Li Z, Jia F et al. Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. Circulation 2011;124:S27-S34.
43. Urbanek K, Cesselli D, Rota M, Nascimbene A, De Angelis A, Hosoda T et al. Stem cell niches in the adult mouse heart. Proc Natl Acad Sci USA 2006;103:9226-9231. (Pubitemid 43902560)
44. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007;104:14068-14073. (Pubitemid 350003336)
45. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-776. (Pubitemid 37186770)
46. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705. (Pubitemid 32290358)
47. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. Circ Res 2011;109:941-961.
48. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998;4:929-933. (Pubitemid 28364032)
49. Power C, Rasko JE. Promises and challenges of stem cell research for regenerative medicine. Ann Intern Med 2011;155:706-713, W217.
50. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. J Am Coll Cardiol 2011;58:1095-1104.
51. Nussbaum J, Minami E, Laflamme MA, Virag JA,Ware CB, Masino A et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 2007;21:1345-1357. (Pubitemid 46684837)
52. Mazo M, Gavira JJ, Pelacho B, Prosper F. Adipose-derived stem cells for myocardial infarction. J Cardiovasc Transl Res 2011;4:145-153.
53. Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017. (Pubitemid 35440281)
54. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-148. (Pubitemid 38891685)
55. Lunde K, Solheim S, Aakhus S, Arnesen H, Moum T, Abdelnoor M et al. Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: results from the Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI) randomized controlled trial. Am Heart J 2007;154:710.e1-710.e8.
56. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet Wet al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006;367: 113-121. (Pubitemid 43077127)
57. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221. (Pubitemid 44427445)
58. Huikuri HV, Kervinen K, NiemeläM, Ylitalo K, Säily M, Koistinen P et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008;29:2723-2732.
59. Tendera M, Wojakowski W, Ruzyllo W, Chojnowska L, Kepka C, Tracz W et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009;30:1313-1321.
60. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-2286.
61. Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009;30:2978-2984.
62. Beitnes JO, Hopp E, Lunde K, Solheim S, Arnesen H, Brinchmann JE et al. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 2009;95:1983-1989.
63. Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011;32:1736-1747.
64. Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011; 32:1748-1757.
65. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006;355:1222-1232. (Pubitemid 44427446)
66. Ang KL, Chin D, Leyva F, Foley P, Kubal C, Chalil S et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med 2008;5:663-670.
67. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117:1189-1200. (Pubitemid 351552018)
68. Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A et al. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv 2009;2:9-16.
69. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention 2011;6:805-812.
70. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847-1857.
71. Seth S, Bhargava B, Narang R, Ray R, Mohanty S, Gulati G et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial a long-term follow-up study. J Am Coll Cardiol 2010;55:1643-1644.
72. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007;167:989-997. (Pubitemid 46835786)
73. Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 2010;7:204-215.
74. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011;8:389-398.
75. Malliaras K, Marbán E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull 2011;98:161-185.
76. Lovell MJ, Mathur A. Cardiac stem cell therapy: progress from the bench to bedside. Heart 2010;96:1531-1537.
77. Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 2011;32: 1197-1206.
78. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. (Pubitemid 350138099)
79. Hinkel R, Trenkwalder T, Kupatt C. Gene therapy for ischemic heart disease. Expert Opin Biol Ther 2011;11:723-737.
80. Williams PD, Kingston PA. Plasmid-mediated gene therapy for cardiovascular disease. Cardiovasc Res 2011;91:565-576.
81. Lavu M, Gundewar S, Lefer DJ. Gene therapy for ischemic heart disease. J Mol Cell Cardiol 2011;50:742-750.
82. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 2011;57:1169-1180.
83. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009;105:724-736.
84. Hedman M, Hartikainen J, Ylä-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther 2011;18:743-749.
85. Hedman M, Muona K, Hedman A, KiveläA, Syvanne M, Eränen J et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009;16:629-634.
86. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-313.
87. Gwathmey JK, Yerevanian AI, Hajjar RJ. Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol 2011;50:803-812.
88. Rissanen TT, Ylä-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007;15:1233-1247. (Pubitemid 46965318)
89. Pacak CA, Byrne BJ. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol Ther 2011;19:1582-1590.
90. Taljaard M, Ward MR, Kutryk MJ, Courtman DW, Camack NJ, Goodman SG et al. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J 2010;159: 354-360.
91. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
92. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. (Pubitemid 36384098)
93. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-1673. (Pubitemid 37378451)
94. Fraccarollo D, Galuppo P, Schmidt I, Ertl G, Bauersachs J. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 2005;67:97-105. (Pubitemid 40798296)
95. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011;123:400-408.
96. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010;120:3350-3364.
97. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-431. (Pubitemid 41040281)
98. Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 2009;11:1099-1105.
99. McSweeney SJ, Hadoke PW, Kozak AM, Small GR, Khaled H, Walker BR et al. Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI. Cardiovasc Res 2010;88:159-167.
100. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009;54:1306-1312.
101. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007;115:1754-1761. (Pubitemid 46648612)
102. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010;121:2437-2445.
103. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol 2008;130:147-158.
104. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009;29:1419-1423.
105. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007;170:818-829. (Pubitemid 47339352)
106. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881-889. (Pubitemid 40604972)
107. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 2006;99: 891-899. (Pubitemid 44556389)
108. Leor J, Rozen L, Zuloff-Shani A, Feinberg MS, Amsalem Y, Barbash IM et al. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation 2006;114:I94-I100. (Pubitemid 44297135)
109. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002;109:41-50. (Pubitemid 34052540)
110. Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci USA 2011;108:1827-1832.
111. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008;371:228-236.
112. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037-3047. (Pubitemid 350179569)
113. Leuschner F, Dutta P, Gorbatov R, Novobrantseva T, Danahoe J, Courties G et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29:1005-1010.
114. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009;54: 130-138.
115. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27:669-692.
116. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-461. (Pubitemid 351599757)
117. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656-661.
118. Hu Y, Zhang H, Lu Y, Bai H, Xu Y, Zhu X et al. Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization. Basic Res Cardiol 2011;106:1311-1328.
119. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010;122:145-155.
120. Jugdutt BI. Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans. Circulation 2010;122:103-105.
121. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95:187-195. (Pubitemid 38988685)
122. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007;74:184-195. (Pubitemid 46517504)
123. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-b signaling in cardiac remodeling. J Mol Cell Cardiol 2011;51:600-606.
124. Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 2010;107:418-428.
125. Laeremans H, Rensen SS, Ottenheijm HC, Smits JF, Blankesteijn WM. Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovasc Res 2010;87:514-523.
126. Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC et al. Blocking of frizzled signaling with a homologous Peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 2011;124:1626-1635.
127. Bujak M, Dobaczewski M, Gonzalez-Quesada C, Xia Y, Leucker T, Zymek P et al. Induction of the CXC chemokine interferon-gamma-inducible protein 10 regulates the reparative response following myocardial infarction. Circ Res 2009;105:973-983.
128. Melchior-Becker A, Dai G, Ding Z, Schäfer L, Schrader J, Young MF et al. Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem 2011;286:17365-17375.
129. Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation 2008;117:1269-1276. (Pubitemid 351365659)
130. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011;123:594-604.